Neuroactive peptides
Neuroactive peptides groups 4 indexed compounds. Also written as neuropeptides, cognitive peptides, neurotropic peptides.
Definition
The compounds grouped here are peptides whose retrieved literature examines effects in the nervous system. The grouping is by the site of the reported activity, not by a shared receptor: a 2006 Brain Research paper reports that Semax, described there as an analogue of ACTH(4-10), regulates BDNF and trkB expression, a 2018 Protein and Peptide Letters review describes Selank as a heptapeptide studied for anxiolytic activity, and a 2012 CNS and Neurological Disorders Drug Targets paper describes Cerebrolysin as a mixture of neurotrophic factors.
[1, 2, 3]Class-level mechanism as reported
No single receptor target unites this class in the retrieved record set, and the records describe different routes. Neurotrophin signalling recurs for Semax: a 2001 Neuroscience Letters paper reports rapid induction of neurotrophin mRNAs in rat glial cell cultures, and a 2010 Cellular and Molecular Neurobiology paper reports transcription of neurotrophins and their receptors. For Selank a 2001 Bulletin of Experimental Biology and Medicine paper reports inhibition of enkephalin-degrading enzymes, and a 2017 Frontiers in Pharmacology paper reports effects on the expression of genes in GABAergic signalling. Cerebrolysin is characterised in a 2012 Drugs of Today review as a neurotrophic preparation rather than a single molecular entity.
[4, 5, 6, 7, 8]Members
| Compound | Other names | Peptide | Reported half-life |
|---|---|---|---|
| Semax | ACTH(4-10) analogue, Met-Glu-His-Phe-Pro-Gly-Pro | Yes | Withheld pending qualified review |
| Selank | tuftsin analogue, Thr-Lys-Pro-Arg-Pro-Gly-Pro | Yes | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
| Cerebrolysin | porcine brain peptide preparation | Yes | Withheld pending qualified review |
| Noopept | omberacetam, GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester | Yes | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
2 of 4 compounds in this class are withheld pending qualified review, so their reported values are not shown here and their pages are not published. They are listed because the class is incomplete without them.
Where this page sits
Research records for compounds in this class
- Records indexed for Semax
- Records indexed for Selank
- Records indexed for Cerebrolysin
- Records indexed for Noopept
Side-by-side pages within this class
All classes: class index. All compounds: compound index.
Sources
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research (2006). pmid:16996037
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters (2018). pmid:30255741
- Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS & neurological disorders drug targets (2012). pmid:22229324
- Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience letters (2001). pmid:11457573
- Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and molecular neurobiology (2010). pmid:19633950
- The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of experimental biology and medicine (2001). pmid:11550013
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in pharmacology (2017). pmid:28293190
- The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of today (Barcelona, Spain : 1998) (2012). pmid:22514792
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.